Postoperative analgesia in orthopedics
Conditions
Interventions
Sufentanil group :Sufentanil 100 µg + Palonosetron 0.5 mg + 0.9% normal saline to 100 ml
Hydromorphone group :Hydromorphone 8 mg + Palonosetron 0.5 mg + 0.9% normal saline to 100 ml
Sponsors
Huzhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Patients scheduled for elective orthopaedic surgery under general anaesthesia and undergoing postoperative PCIA; (2) ASA class I-II; (3) Age 18-65 years and gender; (4) BMI in the range of 18.5-29 kg/m^2.
Exclusion criteria
Exclusion criteria: (1) Combined with serious diseases of heart, brain, liver, kidney and haematopoietic system; (2) Degree II or higher atrioventricular block, bradycardia (HR<50 beats/min), and hypotension (SBP<90mmHg); (3) History of neurological disease; history of chronic pain; history of alcohol abuse; (4) Patients with abuse of analgesic or sedative medications, or a known history of opioid allergy; (5) Those with neurological, psychiatric, or speech impairments that preclude pain assessment; (6) Those with poor compliance and unable to co-operate with the procedure; (7) Those who have participated in a clinical trial of another drug within 3 months; (8) Other patients whom the investigator considers unsuitable for enrolment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score of VAS activity ; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS resting pain score ;The total number of PCAs;The effective times of PCA;The occurrence times of remedial analgesic medication;Rescue analgesic dose;The consumption of PCA in the patient's analgesic pump;Evaluation of patients' satisfaction with analgesia;The incidence rates of drowsiness or difficulty in awakening, skin itching, vertigo, nausea and vomiting, respiratory depression and other adverse reactions; | — |
Countries
China
Contacts
Public ContactZhang Qin
Huzhou Central Hospital
Outcome results
None listed